INTRODUCTION
Aspergillus fumigatus is a filamentous, cosmopolitan and ubiquitous saprophytic fungus [1] . Its natural ecological niche is soil, from which aerosols of conidia are released. If these reach the alveoli in the human lung, they may germinate and start an infection (colonization), leading to invasive or chronic aspergillosis, especially in immunocompromised patients. In these patients, the incidence of invasive infection can be as high as 50 %, with a 50% mortality rate [2] . In the U.S.A., aspergillosis is the second most common opportunistic fungal infection in immunocompromised patients, accounting for as many as 20 % of fungal infections in patients who have received organ transplants [3] . Amphotericin B has long been the primary drug for the treatment of aspergillosis, although voriconazole has been described to represent an improvement against invasive aspergillosis [4] , with itraconazole also providing some encouraging results [5] . Nevertheless, new drugs are urgently needed due to the inefficacy and side effects reported for amphotericin, itraconazole and voriconazole [6] .
The fungal cell wall is essential for the viability of Aspergillus fumigatus and is mainly composed of a branched β(1,3)-glucan core bound to chitin, galactomannan and β (1, 4 )-glucan, embedded in an amorphous cement composed of α(1,3)-glucan, galactomannan and polygalactosamine [7] . Chitin is a β (1, 4) linked polymer of GlcNAc (N-acetylglucosamine), deposited by chitin synthase. Chitin, although a minor component of the A. fumigatus cell wall, is essential for cell viability and motherdaughter cell separation [8] . Chitin biosynthesis, which requires UDP-GlcNAc, is complex and involves several chitin synthases and ancillary proteins [8] . Normal levels of UDP-GlcNAc are required for chitin biosynthesis and subsequent cell wall assembly and growth [9] . UDP-GlcNAc is also a substrate for the synthesis of GPI (glycosylphosphatidylinositol) anchors of cell wall proteins [10] and the synthesis of N-linked and O-linked glycans.
The UDP-GlcNAc biosynthetic pathway is formed by four enzymes. The first enzyme, GFA1 (glutamine:fructose-6-phosphate amidotransferase), is bifunctional, converting fructose-6-phosphate and glutamine into GlcN-6P (glucosamine-6phosphate) [11] . The second enzyme in the pathway is GNA1 (D-glucosamine-6-phosphate N-acetyltransferase), which converts AcCoA (acetyl-CoA) and GlcN-6P into CoA and GlcNAc-6P (N-acetylglucosamine-6-phosphate) [11] . The third enzyme, GlcNAc phosphomutase, converts GlcNAc-6P into GlcNAc-1P, employing glucose-1,6-bisphosphate as a co-factor [12] . The final enzyme, UDP-N-acetylglucosamine pyrophosphorylase, converts UTP and GlcNAc-1P into UDP-GlcNAc and pyrophosphate [11, 13] . GNA1 belongs to the superfamily of GNATs (GCN5related N-acetyltransferases), widely distributed in nature, which use acyl-CoAs to acylate their cognate substrates [14] . Examples of key members of this superfamily include: aminoglycoside, serotonin and glucosamine-6-phosphate N-acetyltransferases, histone acetyltransferase, mycothiol synthase, protein α-Nmyristoyltransferase and the FEM family of acyltransferases [14] . More than 24 crystal structures of members of this superfamily have been solved, and, despite poor sequence conservation, they all have in common a structurally conserved α/β fold [14] .
The key role that GNA1 plays in eukaryotes was first highlighted by a report of Saccharomyces cerevisiae gna1 disruption, producing a lethal phenotype [15] . It was later reported that Candida albicans lacking gna1 was viable only in medium containing high concentrations of N-acetylglucosamine, and showed significantly reduced virulence in a murine model of candidiasis [16] . Although this appears to genetically validate GNA1 as a potential antifungal drug target, it has also been described that the inactivation of the mouse gna1 gene is lethal [17] , reflecting the essential role of this enzyme in higher eukaryotes. Therefore it is imperative to identify structural differences between human and A. fumigatus GNA1 that would be exploitable for selective antifungal drug design. In the present study, we have investigated such potentially exploitable differences in the active sites of HsGNA1 (human GNA1) and Af GNA1 (A. fumigatus GNA1) with the aim of providing further validation of GNA1 as a drug target for the treatment of aspergillosis. We present high-resolution crystal structures of Af GNA1 and HsGNA1 in complex with products, and the kinetic characterization of these enzymes. By detailed comparison of the active sites of both enzymes, potentially exploitable differences are revealed and validated using site-directed mutagenesis.
MATERIALS AND METHODS

Cloning of Af GNA1 and HsGNA1
The A. fumigatus gna1 gene was obtained by PCR from genomic DNA using the forward primer 5 -GGATCCATG-ACCAACGCAACCATTGCTCCGAC-3 and the reverse primer 5 -CTCGAGTCATCAGTAGTAGTGCGCCATCTCCAAC-3 which contain BamHI and XhoI restriction sites. The PCR product was cloned into the pCR2.1 vector (Invitrogen) and subsequently digested with BamHI and XhoI and sub-cloned into the pGEX6P1 vector [which encodes a GST (glutathione transferase) tag and a PreScission protease cleavage site; Amersham Biosciences]. Site-directed mutants were generated following the QuikChange ® protocol (Stratagene), using the KOD HotStart DNA polymerase (Novagene). All plasmids were verified by sequencing (College of Life sciences, University of Dundee, Dundee, Scotland, U.K.). DNA encoding full-length (amino acids 1-184) HsGNA1 was amplified by PCR from the Mammalian Gene Collection clone (accession code gi:37620194) and subcloned into a modified pET28a-MHL vector (http://www.sgc. utoronto.ca/SGC-WebPages/toronto-vectors.php), downstream of the poly-histidine coding region.
Expression and purification
pGEX6P1-Af GNA1 was transformed into BL21 (DE3) pLysS and grown in LB (Luria-Bertani) medium with 50 μg/ml ampicillin. Cells were grown at 37 • C until reaching an optical density of 0.6 at 600 nm, after which the expression of the protein was induced with 0.25 mM IPTG (isopropyl β-D-thiogalactoside) at room temperature (23 • C) for an overnight incubation. The cells were harvested by centrifugation at 3480 g for 30 min and resuspended in a buffer [consisting of 25 mM Tris/HCl and 150 mM sodium chloride (pH 7.5)], containing a small spatula of lysozyme and DNAse, and one tablet of protease inhibitors cocktail (Calbiochem). The cells were disrupted by sonication and centrifuged at 19 000 g at 4 • C for 30 min. The supernatant was incubated at 4 • C with glutathione-Sepharose 4B beads (Amersham Biosciences) previously equilibrated with the same buffer for 2 h and subsequently the GST was cleaved overnight with PreScission protease. The Af GNA1 protein was released from the beads and passed through a pre-equilibrated gel-filtration column as the last step of the purification. The protein was concentrated and analysed by SDS/PAGE. Purification yield was 3 mg of the protein per 1 litre of culture.
HsGNA1 was expressed in Escherichia coli BL21 (DE3) codon plus RIL strain (Stratagene) in TB (Terrific Broth) in the presence of 50 μg/ml of kanamycin. Cells were grown at 37 • C to a D of 1.5 and induced by 1 mM IPTG and incubated overnight at 15 • C. Cells were harvested by centrifugation at 3480 g for 30 min at 4 • C. The cell pellets were frozen in liquid nitrogen and stored at − 80 • C. For the purification, the cell paste was thawed and resuspended in lysis buffer [50 mM Hepes/NaOH (pH 7.4), 500 mM NaCl, 5 mM imidazole, 2 mM 2-mercaptoethanol and 5 % (v/v) glycerol] with protease inhibitor (0.1 mM PMSF). The cells were lysed by passing through a microfluidizer (Microfluidics) at 20 000 lbf/in 2 (1 lbf/in 2 = 6.9 kPa). The crude extract was cleared by centrifugation (19 000 g for 30 min at 4 • C). The clarified lysate was loaded on to a 5 ml HiTrap chelating column (Amersham Biosciences), charged with Ni 2+ . The column was washed with 10 column volumes of 20 mM Hepes/NaOH (pH 7.4), containing 500 mM NaCl, 50 mM imidazole and 5 % (v/v) glycerol, and the protein was eluted with elution buffer [20 mM Hepes/NaOH (pH 7.4), 500 mM NaCl, 250 mM imidazole and 5 % (v/v) glycerol]. The protein was dialysed against 20 mM Hepes/NaOH (pH 7.4), 500 mM NaCl and 5 % (v/v) glycerol in the presence of TEV (tobacco etch virus) protease. The dialysed protein was passed through a 5 ml Ni 2+ HiTrap column and loaded on to a Superdex200 column (26 mm×60 cm; Amersham Biosciences), equilibrated with 20 mM Pipes buffer and 250 mM NaCl (pH 6.5) at a flow rate of 4 ml/min. The pooled fractions containing HsGNA1 were further purified to homogeneity by ion-exchange chromatography on a Source 30S column (10 mm×10 cm; Amersham Biosciences), equilibrated with 20 mM Pipes (pH 6.5), and eluted with a linear gradient of NaCl up to a concentration of 500 mM (20 column volumes). The purification yield was 25 mg of the protein per 1 litre of culture.
Kinetics
Steady-state kinetics of WT (wild-type) and mutant enzymes were determined using a previous described protocol [18, 19] with some modifications. AcCoA, GlcN-6P and CoA were supplied by Sigma. All measurements were performed in triplicate. Standard reactions consisted of 5 nM Af GNA1 (200 nM for the Af GNA1 mutants) or 20 nM HsGNA1 in 25 mM Tris/HCl, 250 mM NaCl, 2 mM EDTA and 5 % (v/v) glycerol (pH 7.5) in a total volume of 50 μl, incubated at room temperature. The reactions were initiated by adding the protein and were stopped at different times depending on the enzyme with 50 μl of a solution containing 25 mM Bis-Tris-propane, 250 mM NaCl, 2 mM EDTA and 6.4 M guanidine chloride (pH 7.5). A 50 μl aliquot of DTNB [dithio-bis(2-nitrobenzoic acid)] solution (1 mM in 0.1 % DMSO) containing 25 mM Tris/HCl, 250 mM NaCl and 2 mM EDTA (pH 7.5) was added and the absorbance at 412 nm was determined. The absorbance was quantified using a Spectra max 340 PC (Molecular Devices). The absorbance intensity data were analysed with non-linear regression analysis using GRAFIT 5 [20] , with the default equations for first-order reaction rates and Michaelis-Menten steady-state kinetics.
Crystallization, phasing and refinement
Two different crystal forms were obtained for Af GNA1. For the first crystal form, Af GNA1 at a concentration of 20 mg/ml was Bar-like shaped crystals (space group C222 1 ) grew within 3 days. The first crystal form was cryoprotected with 30 % PEG 3350 and the second crystal form was cryoprotected using 35 % PEG 1000 and 10 % PEG 8000 in the corresponding mother liquor, and frozen in a nitrogen gas stream cooled to 100 K. A SAD phasing strategy was employed on a P4 3 2 1 2 crystal soaked for 30 min in mother liquor containing 20 mM PbCl 2 , using data collected at the European Synchrotron Radiation Facility (beamline BM14). Data were processed with the HKL suite [21] . Seven lead sites were located and refined with SHELX [22] . This resulted in phases to 2.2 Å (1 Å = 0.1 nm) with a figure of merit of 0.30, yielding a readily interpretable electron-density map. Phases were further improved by solvent-flattening, resulting in an electron density map that showed well-defined density for the protein, and was used for autotracing with warpNtrace [23] , which built 143 out of 190 residues. The resulting model was improved by partial iterative refinement with REFMAC5 [24] interspersed with model building with COOT [25] . This partial model was then used to solve the structure of the C222 1 crystal form by molecular replacement with MOLREP [26] against 4 Å data (Table 1) , giving a single solution (R-factor = 0.372) with one molecule in the asymmetric unit. Further refinement to 1.8 Å with REFMAC5 including TLS, interspersed with model building with COOT [25] yielded a model with the final statistics shown in Table 1 . Models for ligands were not included until their conformations were welldefined by the unbiased |F o | − |F c |, ϕ calc electron-density maps (Figure 4) . Ligand topologies and co-ordinates were generated with PRODRG [27] . In the case of the CoA, the last seven atoms including the sulfhydryl group were not well-defined by the electron-density maps and were omitted from the model. WHAT IF [28] was used to check hydrogen bonds and PyMOL [29] was used to generate pictures. Purified HsGNA1 (16 mg/ml) was crystallized using the sitting-drop vapour-diffusion method by mixing 1 μl of protein solution with 1 μl of the reservoir solution containing 25 % PEG 4000, 0.2 M ammonium sulfate, 0.1 M sodium acetate, (pH 4.6) and 0.1 M yttrium chloride. For the ternary complex, purified HsGNA1 protein was complexed with CoA and GlcNAc-6P (Sigma) at a 1:5:5 molar ratio of protein/CoA/GlcNAc-6P and crystallized using the hanging-drop vapour-diffusion method by mixing 2 μl of protein solution with 2 μl of the reservoir solution containing 27 % PEG 3350, 0.2 M MgCl 2 and 0.1 M bicine (pH 9.0). Crystals were soaked in the corresponding mother liquor supplemented with 20 % (v/v) glycerol as cryoprotectant before freezing in liquid nitrogen. X-ray diffraction data were collected at 100K at beamline 17ID of APS (Advanced Photon Source) at Argonne National Laboratory (Argonne, IL, U.S.A.). Data were processed using the HKL 2000 software package [21] . The structure of apo-HsGNA1 was solved by molecular replacement using the program MOLREP [26] with the yeast GNA1 structure (PDB 1I1D [30] ) as the search model and was partially refined. The partial model was then used as a molecular replacement search model against the ternary complex diffraction data. ARP/wARP was used for automatic model building [23] using the initial model phases. The graphics program COOT [25] was used for model building and visualization. Crystal diffraction data and refinement statistics are displayed in Table 1 .
RESULTS AND DISCUSSION
Kinetics of Af GNA1 and HsGNA1
Af GNA1 and HsGNA1 were PCR-amplified and cloned into vectors suitable for overexpression in E. coli as GST-fusion and His-tagged proteins respectively. Purification using affinity, ion-exchange and size-exclusion chromatography yielded 4 mg and 25 mg of pure Af GNA1 and HsGNA1 per litre of bacterial culture respectively.
Af GNA1 and HsGNA1 steady-state kinetics were studied under linear conditions and with no more than 15 % of product formation. Both enzymes displayed classical Michaelis-Menten kinetics (Figure 1) . Af GNA1 showed a K m for AcCoA of 40 + − 6 μM, K m for GlcN-6P of 71 + − 6 μM and k cat of 38 + − 3 s −1 (the maximal specific activity was 107 μmol · min −1 · mg −1 at pH 7.5). Under the same conditions HsGNA1 showed a similar K m for AcCoA and GlcN-6P, being 26 + − 3 μM and 97 + − 12 μM respectively. The k cat of the human enzyme was 9 + − 0.2 s −1 (the specific activity was 25 μmol · min −1 · mg −1 ). Overall, the fungal enzyme (k cat /K m = 0.95 s −1 · μM −1 ) was 3-fold more catalytically efficient for AcCoA than the human enzyme (k cat /K m = 0.34 s −1 · μM −1 ). The catalytic efficiency for GlcN-6P was 6-fold higher for Af GNA1 compared with HsGNA1 (k cat /K m = 0.53 and 0.092 s −1 · μM −1 respectively). In terms of the maximal specific activity previously reported for GNA1 from various sources, the range is from 0.0054 to 12.2 μmol · min −1 · mg −1 , indicating that Af GNA1 would be one of the fastest GNA1s described so far (107 μmol · min −1 · mg −1 ) [31, 32] .
Af GNA1 and HsGNA1 adopt the GNAT fold
To understand the source of the kinetic differences observed between Af GNA1 and HsGNA1 and to study potential amino acid differences in their active sites, the crystal structures of these enzymes were solved and refined against high-resolution synchrotron diffraction data. An apo-Af GNA1 structure was solved using a lead SAD experiment with a P4 3 2 1 2 crystal form ( Table 1) . A partially refined model from this was then used to solve a C222 1 crystal form of the Af GNA1 CoA-GlcNAc-6P complex by molecular replacement, subsequently refined to 1.80 Å resolution with an R-factor of 0.177 (R free = 0.215; Table 1 ). An apo-HsGNA1 structure was solved by molecular replacement with a C2 crystal form and partially refined. The resulting model was then used to solve a P2 1 crystal form of the HsGNA1 CoA-GlcNAc-6P complex by molecular replacement followed by refinement to 1.8 Å resolution with an R-factor of 0.189 (R free = 0.237; Table 1 ).
Both Af GNA1 and HsGNA1 are homodimers in the crystal (and solution) and adopt essentially the same fold as the first GNA1 structure solved, that of S. cerevisiae (ScGNA1) [30] ( Figure 2A ; 0.98 Å on 147 Cα atoms and 1.18 Å on 146 Cα atoms for Af GNA1 and HsGNA1 superposed on the ScGNA1 crystal structure respectively). Thus the typical signature of the GNAT superfamily is also present: an N-terminal strand (β1) followed by three α helices (α3-α4-α5), three antiparallel β strands, a signature central helix (α8), a fifth β strand, two α helices (α9 and α10) and a sixth and final β strand (Figure 2A ). The only difference in secondary structure between the human and the fungal enzymes is that HsGNA1 has a short additional β strand (β6, Figure 2A) . A superposition of Af GNA1 and HsGNA1 monomers gives an RMSD (root mean square deviation) of 1.3 Å on 159 Cα atoms, suggesting some conformational differences. Most of these differences are located to α1, α2, α5, α7, β2, β3 and β6, with α7 and β6 contributing residues to the substrate-binding site. Similarly, a sequence alignment between the two GNA1s shows that while these proteins share the four GNAT motifs (Figure 2B) , the sequence identity is only 30 %. These significant structural and sequence differences prompted an investigation of whether such differences also extended to the active site.
Af GNA1 and HsGNA1 possess different GlcN-6P subsites
A close inspection of the active sites of both enzymes showed that although the AcCoA-binding site is essentially conserved, significant differences are present in the GlcN-6P-binding site (Figures 3 and 4) . The main differences are located to the residues contacting the α face of the sugar (Figures 3 and 4) . These residues are, in Af GNA1, Val 125 , Gly 183 , Glu 185 and Tyr 189 , with the equivalent residues in HsGNA1 being Arg 116 , Glu 175 , Tyr 177 and Arg 181 respectively. Arg 116 , Glu 175 and Arg 181 of the human enzyme directly contact the sugar product, whereas Tyr 177 lines a pocket just below it (Figure 4) . Interestingly, the two arginine residues are substituted by smaller, neutral residues in the fungal enzyme, presumably with a reduced ability to interact with the phosphate on the sugar. Furthermore, the substitution of a glutamate residue (Glu 175 ) with a glycine (Gly 183 ) residue in the fungal enzyme generates a larger binding cavity. Thus the HsGNA1 and Af GNA1 active sites show significant differences around the sugar-binding site.
Catalytic properties of Af GNA1-HsGNA1 chimaeras
To study the contributions to substrate binding of the different residues lining the sugar-binding site, Af GNA1-HsGNA1 chimaeras were constructed through site-directed mutagenesis, and their kinetic properties were studied ( Table 2) . Although all four mutant enzymes show effects in terms of reduced catalytic efficiency, this is, surprisingly, not only due to increases in K m , but also decreases in k cat . V125R and G183E show the largest effects on k cat , with a 327-fold and 112-fold decrease respectively, compared with the Af GNA1 WT ( Table 2 ). V125R also shows the largest effects on the K m s for AcCoA and GlcN-6P, with a 5-fold and 8.5-fold decrease in the K m of AcCoA and the K m of GlcN-6P respectively. Apparently, the arginine residue present at this position in the human enzyme facilitates binding of the sugar substrate through interaction with the phosphate group (Figure 4 ). The precise positioning of the sugar could be important for the direct nucleophilic attack mechanism proposed previously [30] , and this could explain the concomittant changes in k cat . A similar explanation of effects on k cat could be applied to the other three mutants which are likely to have effects on the precise position of the sugar in the binding site. Thus mutation of the four nonconserved residues lining the sugar-binding pocket suggests that they contributed to the kinetic differences between the Af GNA1 and HsGNA1 enzymes. . Secondary structure is shown in olive (strands) and brown (helices) for one monomer, and blue (helices) and red (strands) for the other monomer. A highly conserved active site tyrosine residue, that has been proposed to stabilize the leaving thiolate during catalysis [30] , is shown as sticks in both crystal structures. CoA and GlcNAc-6P are shown as sticks with green carbon atoms. In the middle of this panel a superposition of the monomers from Af GNA1 (blue) and HsGNA1 (red) are shown. (B) Multiple sequence alignment between Af GNA1, HsGNA1, CeGNA1 (Caenorhabditis elegans GNA1), ScGNA1, CaGNA1 (C. albicans GNA1), DmGNA1 (Drosophila melanogaster GNA1), MmGNA1 (Mus musculus GNA1), CpGNA1 (Culex pipiens GNA1), AeGNA1 (Aedes aegypti GNA1). Magenta triangles represent the residues from either Af GNA1 or HsGNA1 involved in the binding of the sugar. The conserved tyrosine residue is shown as a green triangle. The four different motifs of the GNAT family are represented as yellow boxes. 
Concluding remarks
There is sufficient data at the genetic level to suggest that GNA1 is an attractive antifungal drug target, provided two key issues can be addressed. First, although substrate-based inhibitors for the larger GNAT family, of which GNA1 is a member, have been reported, they do not possess drug-like properties and no significant in vivo effects of these molecules have been reported [33] [34] [35] . Secondly, the issue of selectivity requires careful consideration as a knockout of the mouse enzyme produced a lethal phenotype and GNA1 is generally believed to be essential in eukaryotes [17] . The latter issue was the focus of the present study, using Af GNA1 and HsGNA1 as model enzymes. Kinetic analysis of these enzymes revealed differences in their Michaelis-Menten parameters. This was then corroborated by determination of their high-resolution crystal structures, which allowed a direct comparison between the active sites of these enzymes. Surprisingly, this revealed that structural differences between the two enzymes were mostly located to the sugar-binding site, whereas the AcCoA-binding site appeared to be more conserved. These changes affect not only the electrostatics, but also reveal a more spacious sugarbinding site in the Af GNA1 enzyme, whereas large side chains at these positions create a tighter pocket in the HsGNA1 enzyme. Probing of these residues using mutagenesis suggests that they are important for sugar binding and positioning. Taken together these results may provide a useful framework for the discovery and/or design of molecules that show selective binding to Af GNA1 over HsGNA1.
Although the work reported in the present study appears to provide data to support future drug discovery aimed at identifying Af GNA1 inhibitors, it has also uncovered a number of issues that may hamper such endeavours. While selective design of inhibitors may be achievable, such molecules may well possess undesir-
Figure 4 Comparison of the Af GNA1 and HsGNA1 active sites
Stereo views of the structures of Af GNA1 (A) and HsGNA1 (B) in complex with CoA and GlcNAc-6P, and detailed comparison of the phosphate-binding sites (C). The protein backbone is shown as a grey ribbon. Residues lining the active site are shown as sticks with grey carbon atoms (conserved residues) or orange carbon atoms (non-conserved residues). Ligands are shown as sticks with green carbon atoms. In the Af GNA1 structure, the terminal atoms of CoA, including the thiol, were omitted from the model due to a lack of electron density. Protein-ligand hydrogen bonds are shown as dotted green lines. Unbiased (i.e. before inclusion of any ligand model) (for Af GNA1) and a simulated annealing omit (for HsGNA1) |F o | − |F c |, ϕ calc electron-density maps are shown at 2.5 σ . Water molecules involved in hydrogen bonds with the ligand or the protein are shown as blue spheres. In (C), protein-phosphate distances (Å) are shown in black.
able properties. The substrate complexes described in the present study and published previously [30] show that interactions with the sugar are mostly of a polar nature, with almost no hydrophobic/ van der Waals interactions. Furthermore, if competition with both sugar and AcCoA (the latter also binding mainly through electrostatic interactions) is sought, the resulting molecules may be of a size beyond the spectrum normally associated with druglikeness [36] . Indeed, the only well-characterized inhibitors known for the GNAT family of enzymes are truncated aminoglycoside-CoA bisubstrate analogues for aminoglycoside 6 -N-acetyltransferase [33] , histone H3 peptides conjugated with CoA for GCN5 histone acetyltransferase [35] and the brominated CoA-S-acetyl-tryptamine bisubstrate analogue for serotonin N-acetyltransferase [34] . Nevertheless, the present study provides structural and kinetic data which may be useful tools in studies towards the discovery of novel GNA1 inhibitors.
